Responses of the external oblique muscle of the abdomen to CRD were measured to evaluate the sensitivity of visceral pain in rats. The sensitivity of visceral pain significantly increased in IBS-like rats. Expressions of spinal NR2B subunit and phosphorylated NR2B subunit significantly increased by 50-55% in IBS-like rats when compared with those in control rats. Ro 25-6981, a selective antagonist of NR2B subunit, has a dose-dependent antiallodynic and anti-hyperalgesic effect without causing motor dysfunction in IBS-like rats.
Introduction
Chronic pain is a major health issue in developed countries. It can affect up to 20% of the adult population and impose a severe economic burden (Saito et al., 2002) . Currently, there are more than 100 million patients with chronic pain including chronic visceral pain (Shinozaki et al., 2008) . Although chronic inflammation and tumors are common pathogenic factors for chronic visceral pain, there are quite a large proportion of patients with chronic visceral pain without pathological alteration, such as irritable bowel syndrome (IBS) (Xu et al., 2008; Elsenbruch, 2011) . Chronic pain remains a clinical challenge due to its unknown etiology (Longstreth, 2005; Asano et al., 2012) .
A proportion of IBS patients display visceral pain hypersensitivity (VPH), which may be the main reason for chronic abdominal pain or diarrhea of IBS (Farmer and Aziz, 2009 ). Central sensitization is thought to play a central role in the development and maintenance of VPH (Sarkar et al., 2000 (Sarkar et al., , 2001 . The N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor, plays a key role in excitatory synaptic plasticity (Qu et al., 2009 ). The activation of NMDA receptors in the spinal dorsal horn is essential to trigger central sensitization (Bleakman et al., 2006; Woolf, 2007) . Our previous study indicated that the NMDA receptor antagonist (AP-7) inhibited the increased responses of lumbosacral neurons to colorectal distention (CRD) in IBSlike rats (Lin and Al-Chaer, 2005) . However, the NMDA receptor antagonists such as AP-7 or MK-801 are not approved for treatment of chronic pain, mainly due to its severe side effects such as motor dysfunction (Chen et al., 2009) .
Subunits composed of NMDAR are classified as family NR1, NR2A-D and NR3, in which NR1 is an essential functional subunit, NR2A-NR2D are modulatory subunits, and the function of NR3 remains unclear (Meguro et al., 1992; Paoletti and Neyton, 2007) . The subtype-specific drugs may show greater promise as analgesics for chronic pain due to their reduced side effects (Boyce et al., 1999; Qu et al., 2009; Xu et al., 2012) . Particularly, spinal cord NR2B subunit is responsible for the central sensitization (Pedersen and Gjerstad, 2008) . Besides, intrathecal injection of the selective NR2B receptor antagonist, Ro 25-6981, can dose-dependently inhibit neuropathic pain without causing motor dysfunction (Qu et al., 2009) . There is growing evidence that there are some differences between the mechanisms of visceral and somatic pain (Wesselmann et al., 2009) . Our previous study has discovered an over-expression of the NR2B subunit at the lumbosacral spinal cord in IBS-like rats (Lin et al., 2008) , but the potential mechanism of its action remains to be clarified.
In the present study, an IBS-like rat was established by CRD on post-natal days 8-14 (Lin et al., 2006) . Visceral pain hypersensitivity was evaluated by measuring amplitude of electromyographic (EMG) to CRD. The expression of spinal NR2B subunit and phosphorylated NR2B subunit was analyzed by western blot. Effects of the selective antagonist of NR2B subunit and the specific inhibitor of tyrosine kinases on visceral hypersensitivity were also evaluated.
Results

2.1.
Neonatal CRD resulted in visceral pain hypersensitivity and enhanced expression of spinal NR2B subunit in adult rats
Responses of EMG to CRD significantly increased in IBS-like rats (Bonferroni T test, Po0.05, Table 1 ). Responses of EMG in IBS-like rats increased by 106% and 69% under 40 and 60 mmHg CRD, respectively, when compared with those in control rats. These data indicated that neonatal CRD resulted in visceral pain hypersensitivity in adult rats. Western blot results showed that expression of spinal NR2B subunit was significantly increased by 55% (from 0.2070.02 to 0.3170.01) in IBS-like rats as compared with that in control rats (SNK-qtest, Po0.05, Fig. 1 ). The expression of spinal NR2B subunit was not affected by intrathecal injection of Ro 25-6981.
2.2.
Ro 25-6981 treatment attenuated visceral pain hypersensitivity in IBS-like rats Ro 25-6981, a selective NR2B subunit antagonist, was intrathecal injected into rats to demonstrate whether the spinal NR2B subunit plays a role in the development of chronic visceral pain. No significant change was observed at 30 min after i.t. 150 μg (the maximum dose) Ro 25-6981 in control rats (Bonferroni T test, P40.05, Fig. 2A ). There was no obvious change between i.t. 25 μg Ro 25-6981 and DMSO in responses of EMG to 40-60 mmHg CRD in IBS-like rats (Bonferroni T test, P40.05, Fig. 3A Fig. 3A and B). Responses of EMG were decreased by 52% (from b r a i n r e s e a r c h 1 5 4 2 ( 2 0 1 4 ) 1 6 7 - Fig. 4A and B).
Phosphorylation of spinal NR2B subunit was inhibited by Ro 25-6981 or genistein in IBS-like rats
The effect of genistein, a tyrosine kinase inhibitor, was investigated to the potential activation mechanism of the spinal NR2B subunit in central sensitization of chronic visceral pain. Expression of phosphorylated NR2B subunit enhanced by 50% (from 0.1970.02 to 0.2970.03) in IBS-like rats as compared with that in control rats. The expression of phosphorylated NR2B subunit was decreased by 38% (from 0.2970.03 to 0.1870.02) at 30 min after i.t. Ro 25-6981 (75 μg), and 31% (from 0.2970.03 to 0.2070.04) at 60 min after i.t. genistein (0.5 mg), respectively, as compared with i.t. DMSO in IBS-like rats (SNK-q-test, Po0.05, Fig. 5B ). The ratio (0.9270.08) of normalized pho-NR2B of normalized NR2B in IBS-like rats was similar with that (0.9670.11) in control rats (SNK-q-test, P40.05, Fig. 5C ). The ratio significantly reduced about 40% (from 0.9370.13 to 0.5670.06) at 30 min after i.t. Ro 25-6981 (75 μg), and 30% (from 0.9370.13 to 0.6570.17) at 60 min after i.t. genistein (0.5 mg), respectively, as compared with i.t. DMSO in IBS-like rats (SNK-q-test, Po0.05, Fig. 5C ).
Tyrosine kinase inhibitor decreased visceral pain hypersensitivity in IBS-like rats
Results showed that no obvious change was observed after genistein injection (1.0 mg, the maximum dose) in control rats (Bonferroni T test, P40.05, Fig. 2B ). There was no obvious change between 0.1 mg genistein and vehicle groups in IBSlike rats (Bonferroni T test, P40.05, Table 2 ). Responses of EMG were decreased by 60% and 34% under 40 and 60 mmHg CRD at 60 min after i.t. 0.5 mg genistein, respectively, as compared with vehicle in IBS-like rats (Bonferroni T test, Po0.05, Table 2 ). Responses of EMG were decreased by 81% and 67% under 40 and 60 mmHg CRD at 60 min after i.t. b r a i n r e s e a r c h 1 5 4 2 ( 2 0 1 4 ) 1 6 7 -1 7 5 1.0 mg genistein, respectively, as compared with vehicle in IBS-like rats. (Bonferroni T test, Po0.05, Table 2 ). Responses of EMG were decreased by 53% and under 40 mmHg CRD, and by 53% under 60 mmHg CRD at 60 min after i.t. 0.5 mg genistein as compared with i.t. 0.1 mg genistein in IBS-like rats (Bonferroni T test, Po0.05, Table 2 ). Responses of EMG were decreased by 54% and 43% under 40 and 60 mmHg CRD at 60 min after i.t. 1.0 mg genistein, respectively, as compared with i.t. 0.5 mg genistein in IBS-like rats (Bonferroni T test, Po0.05, Table 2 ). These results suggested that genistein had a dose-dependent anti-allodynic and anti-hyperalgesic effect, which implied that tyrosine phosphorylation was the one of activation mechanisms of the spinal NR2B subunit in central sensitization of chronic visceral pain.
Time course of inhibition effect of genistein on chronic visceral pain in IBS-like rats
The amplitude of EMG was recorded every half an hour within 2.5 h after i.t. genistein under 40 and 60 mmHg CRD in IBS-like rats. The lowest amplitude was 8.1675.93 μV and 10.6576.66 μV under 40 and 60 mmHg CRD, respectively, at 60 min after i.t. genistein (0.5 mg). Responses of EMG to CRD were basically recovered at 2.5 h after i.t. genistein. Responses of EMG to 40-60 mmHg CRD were lowered by 47-60% and 27-38%, respectively, at 60 and 90 min after i.t. 0.5 mg (medium dose) genistein. These results indicated the best time point for optimal anti-allodynic effect was observed at 60 min after i.t. of genistein under either 40 or 60 mmHg CRD in IBS-like rats (Bonferroni T test, Po0.05, Fig. 4C and D) .
Discussion
We have previously demonstrated that the responses of lumbosacral neurons to CRD were enhanced in IBS-like rats. The NMDA receptor antagonist AP-7 inhibited the enhanced neuronal activity in IBS-like rats (Lin and Al-Chaer, 2005) . In the present study, we further provide new evidence to demonstrate that the spinal NR2B receptor plays a key role in the development of visceral hypersensitivity and that NR2B receptor activities are regulated by tyrosine kinase. Firstly, the expressions of the spinal NR2B subunit and phosphorylated NR2B subunit increased in IBS-like rats as compared with those in control rats. Secondly, enhanced phosphorylation of spinal NR2B subunit was inhibited after spinal administration of the selective antagonist of NR2B subunit, Ro 25-6981, or the tyrosine kinase inhibitor, genistein, in IBS-like rats. Thirdly, visceral pain hypersensitivity was significantly reduced by i.t. Ro 25-6981 or genistein in IBSlike rats as compared with that in control rats.
Role of spinal NR2B subunit in central sensitization of chronic visceral pain
There is growing evidence that there are some similarities and differences between the mechanisms of visceral and somatic pain (Wesselmann et al., 2009) 
have revealed that central sensitization of somatic pain was mediated by spinal NMDA receptor, especially NR2B subunit (Renno, 1998; Pedersen and Gjerstad, 2008; Hu et al., 2009) . Though central sensitization is also thought to play a central role in the development and maintenance of visceral pain (Sarkar et al., 2000 (Sarkar et al., , 2001 , its mechanism is still unclear. In our previous studies, the increased responses of lumbosacral neurons to CRD were inhibited by the NMDA receptor antagonist, AP-7, in IBS-like rats (Lin and Al-Chaer, 2005) . In addition, the expression of the NR2B subunit at the lumbosacral spinal cord was enhanced in IBS-like rats by the immunohistochemical method (Lin et al., 2008) . In the present research, over-expression of spinal NR2B subunit was further confirmed by Western Blot analysis. Furthermore, the NR2B subunit antagonist, Ro 25-6981, could dose-dependently attenuate visceral pain in IBS-like rats. Therefore, we can infer reasonably that spinal cord NR2B subunit is also responsible for the central sensitization in visceral pain, similar to inflammatory and neuropathic pain (Qu et al., 2009; Hu et al., 2009 ). Visceral pain hypersensitivity includes allodynia and hyperalgesia: allodynia implies that an originally non-noxious stimulation can induce pain; hyperalgesia indicates that an originally noxious stimulation can induce a supernormal reaction (Al-chaer et al., 2000; Zhuo, 2007; S. Li et al., 2011a ; X.Y. Li et al., 2011b) . In our present study, i.t. Ro 25-6981, the NR2B subunit selective antagonist, attenuated visceral pain by 77% under 40 mmHg CRD (a non-noxious stimulation), and by 64% under 60 mmHg CRD (a noxious stimulation). So, Ro 25-6981 attenuated not only allodynia, but also hyperalgesia in rats with chronic visceral pain.
Several lines of evidence support the notion that Ro 25-6981 exerted its analgesic effect via action on the spinal NR2B subunit in the present study. Firstly, Ro 25-6981 is applied to the spinal cord by intrathecal injection so that spinal cord is its target scope in the behavioral experiments. Secondly, Ro 25-6981 is 5000 folds more selective for the heteromeric NR1/ NR2B receptors than the NR1/NR2A receptors (Fischer et al., 1997) . Thirdly, spinal NR2B expression increased by 55%, and Ro 25-6981 could dose-dependently attenuate visceral pain hypersensitivity in IBS-like rats. Taken together, our results provide strong evidence that the spinal NR2B subunit plays an important role in the central sensitization of chronic visceral pain. The reason why Ro 25-6981 did not completely attenuate visceral pain hypersensitivity is likely because of the low dose of Ro 25-6981 or its complicated mechanisms. Other signaling molecules such as non-NMDA receptors may mediate chronic visceral pain (Lin and Al-Chaer, 2005) .
Contribution of tyrosine phosphorylation of spinal NR2B subunit to central sensitization of chronic visceral pain
The NR2B subunit is a membrane glycoprotein with an approximate molecular mass of 170-180 kDa, which is composed of an extracellular N terminus that binds allosteric inhibitors with an S1-S2 agonist-binding domain, a transmembrane region that forms the ion channel and a C-terminal cytoplasmic region that binds to phosphorylation sites by protein kinase, such as PKC and tyrosine kinase (Hollmann et al., 1993; Mony et al., 2009 ).
Tyrosine kinase activation-induced phosphorylation of NR2B subunit contributes to the central sensitization among the signal transduction pathways (Xiong et al., 1999 , Liu et al., 2004 . There is potent evidence that the activation of tyrosine phosphorylated NR2B in the spinal cord is abolished by a tyrosine kinase inhibitor, genistein, in inflammatory pain (Ali and Salter, 2001 ). In agreement with the studies in the inflammatory hyperalgesia reported by Guo et al. (2002) , our results also show that genistein (i.t.) could inhibit visceral hypersensitivity and block the over-expression of tyrosine phosphorylated NR2B subunit in spinal cord in IBS-like rats. The abovementioned results indicate that there may be a similar activation mechanism of spinal NR2B between visceral pain and inflammatory pain. Meanwhile, it is reasonable to draw a conclusion that the tyrosine phosphorylation could be one of the activation mechanisms of spinal NR2B subunit in the central sensitization of chronic visceral pain.
The ratio of pho-NR2B in total NR2B apparently increased in inflammatory pain and the postoperative hyperalgesia induced by remifentanil (Gu et al., 2009) . Our results showed the ratio did not significantly increase in IBS-like rats when compared with that in control rats. However, total NR2B and phosphorylated NR2B in IBS-like rats significantly increased when compared with those in control rats. It appears that the most of increased NR2B was phosphorylated in IBS-like rats, namely the significant enhancement of expression level of total NR2B results in apparent increases in pho-NR2B. We have several reasons to explain this phenomenon. Firstly, there are some fundamental differences between the mechanisms responsible in visceral and somatic pain (Wesselmann et al., 2009 ). Secondly, inflammatory pain and the postoperative hyperalgesia induced by remifentanil are acute or sub-chronic pain (few days up to 1 month), while the visceral pain established in this present study is a chronic pain (at least 2 months). Chronic stimulation may result in up-regulating the NR2B subunit. Thus, there are both similarities and differences in the mechanisms of visceral and somatic pain.
Visceral pain was attenuated by 77%, 64% respectively under 40 and 60 mmHg CRD after i.t. Ro 25-6981, 54%, 43% respectively after i.t. genistein. Genistein did not attenuate visceral pain hypersensitivity as much as Ro 25-6981 is likely because that there are other signaling pathways in the activation mechanism of spinal NR2B subunit. In addition, NR2B subunit has seven phosphorylation sites for tyrosine kinase, with its main phosphorylation sites including S1303, S1323, S1480, Y1252, Y1336, and Y1472 (Nakazawa et al., 2001; Qiu et al., 2011) . In this study, western blot results showed that expression of Tyr-1472 of NR2B in spinal cord significantly enhanced in IBS-like rats as compared with that in control rats. Thus, spinal NR2B phosphorylation at tyrosine 1472 contributed to spinal sensitization of chronic visceral pain, which is similar with the results in NMDA-induced pain hypersensitivity reported by S. Li et al., (2011a) .
3.3.
The superiority of NR2B subunit for treatment of chronic visceral pain Chronic visceral pain of IBS is treated mainly by medications and acupuncture. However, currently available pharmacological treatments for IBS show only moderately improved efficacy over placebo without curing the underlying disease itself (Drossman et al., 2008; Farmer and Aziz, 2009; Wesselmann et al., 2009) . NMDA receptor antagonist MK-801 has been shown to significantly relieve chronic visceral pain by inhibiting spinal sensitization. However, this type of nonspecific subunit receptor antagonist may induce severe side effects such as learning and memory impairment, sensory or motility disorders, and hyperactivity (Jevtovic-Todorovic et al., 1998) . The good news is that subtype-specific drugs which selectively target NR2B subunit-containing receptors may show greater promise as analgesics for neuropathic pain due to their reduced side effects (Boyce et al., 1999; Qu et al., 2009; Xu et al., 2012) . The NR2B subunit selective antagonist, Ro 25-6981, is more selective than MK-801 (Fischer et al., 1997) . In our experiment, no significant side effects were observed up to the maximum dose of Ro 25-6981, which was in conformity with the results in neuropathic pain reported by Qu et al. (2009) .
There are conflicting studies on the efficacy of acupuncture treatment for functional visceral pain in patients with IBS (Lembo et al., 2009; Liu et al., 2009; Shi et al., 2012) . In the experiment, Ro 25-6981 reduced visceral pain by 77% and 64%, respectively, under 40 and 60 mmHg CRD in IBS-like rats. Cui et al. reported that acupuncture treatment could respectively decrease chronic visceral pain by 45% and 40% under 40 and 60 mmHg CRD in IBS-like rats (Cui et al., 2005) . This shows Ro 25-6981 has a stronger effect than acupuncture treatment in pain-relief. Thus, the NR2B receptor antagonist, Ro 25-6981, is demonstrated to be a high-efficiency and lowtoxicity candidate for relieving chronic visceral pain.
In summary, our results imply that the increase of visceral pain hypersensitivity in IBS-like rats was mediated by the spinal NMDA receptor NR2B subunit. In addition, the underlying activation mechanism of the spinal NR2B subunit appears to be via tyrosine phosphorylation.
4.
Experimental procedures
Animals
Male Sprague-Dawley neonatal rats (younger than 5 days) were provided by the Department of Experimental Animal Center at Fujian Medical University. The animals were housed with a nursing adult female rat until they were 25 days old. After separation from the adult female rats, the weaned male rats were raised for at least 2 months before surgery and housed six in a cage with access to food and water ad libitum. The animal experimental procedures were conducted in accordance with the guidelines of the International Association for the Study of Pain (Zimmermann, 1983) . The experiments were approved by the Animal Care and Use Committee of Fujian Medical University.
Animal model of visceral hyperalgesia
In order to investigate mechanisms of pain in IBS sufferers, we developed a modified rat model of chronic visceral pain, based on an IBS model reported by Lin and Al-Chaer (2003) .
Daily 60 mmHg CRD was performed on neonatal rats beginning 8-14 days after birth (Lin et al., 2006) . Compared with the model reported by Lin and Al-Chaer (a daily pressure of 60 mmHg CRD stimulation at days 8-21 after birth), the model we established showed a lower mortality and a higher rate of success. The responses of EMG to CRD in IBS-like rats are consistent with those reported by Lin and Al-Chaer (2003) .
The distention was applied using vascular reconstruction balloon (length: 20.0 mm; diameter: 2.5 mm) inserted into the descending colon through the rectum of awake rats. The balloon was quickly distended with 60 mmHg for 1 min and then deflated and withdrawn. The control rats received the same procedure except CRD. After the distention stimulus was terminated, the rats were kept until they reached adulthood (at least 8 weeks old), and then experiments were performed.
Assessment of visceral hypersensitivity
Visceral hypersensitivity of rats (8 weeks old) were evaluated by recording electromyography (EMG) from the external oblique muscle of abdomen (EOMA) in responses to CRD stimulation under anesthesia with isoflurane by anesthesia machine (VMR, Matrx, USA). CRD stimulus was applied using an inflatable balloon (constructed from no. 7 latex, 6 cm in length, which was inflated with air overnight before the experiment) attached to an intravenous line via a T connector that was also attached to a 10-ml syringe and a sphygmomanometer. A collapsed non-distensible balloon was inserted into the anus and advanced into the colorectum using glycerol while the animal was anesthetized, 1 cm from the base of the balloon to the anus. After the balloon was advanced into the colon, it was secured by taping the attached tubing to the rat's tail. Silver bipolar electrodes were inserted above the inguinal ligament on the side of the external oblique 1.5 cm away from the midline, and then an appropriate dose of anesthetic was administered. Generally, the vaporizer scale was adjusted to about 1 and maintained the constant dose continuously when evaluating visceral hypersensitivity of rats, so that the rats were in a state of light anesthesia. Subjective indicator of light anesthesia is that experimental rats have no spontaneous activity but have perception of pain induced by pinching posterior limb using hemostatic forceps. The balloon was inflated to 40 and 60 mmHg for 10 s followed by 4 min rest. In the present experiment, 40 and 60 mmHg CRD were selected to lower colorectal stimulation of rats whereas Lin et al. used 20, 40, 60 , and 80 mm Hg CRD. The pressure of 40 mmHg CRD is a non-nociceptive stimulation, and 60 mmHg CRD pressure is a nociceptive stimulation (Al-Chaer et al., 2000) . The magnitude of EMG activity was measured by a RM6240BD multi-channel physiological signal acquisition and processing system (the instrument, made in Chendu, China). (Parameter settings: high-frequency filtration of 3 kHz, time constant of 0.001, sampling frequency of 40 Hz, sensitivity of 200 μV, and paper speed of 200 ms/div.) The software of the system recorded 20 amplitudes during each 10 s distention period, and their mean amplitude was representative for magnitude of EMG.
In the statistical analysis, data of EMG were derived from mean amplitude of EMG during each 10 s of distention b r a i n r e s e a r c h 1 5 4 2 ( 2 0 1 4 ) 1 6 7 -1 7 5 subtracting the mean baseline amplitude for the 10 s predistention period for each pressure in order to avoid influence of baseline before CRD. In order to avoid the interference of other factors, a single blind operation was adopted in the experiment. Furthermore, the rats were kept in a quiet environment, with relative humidity maintained at 40-70% and room temperature at 23-27 1C.
Intrathecal catheter implantation
Implantation of intrathecal cannula (i.t.) was performed under chloral hydrate (0.3 g/kg, i.p.) anesthesia according to the method of Størkson et al. (1996) . Briefly, a PE-10 polyethylene catheter (Becton Dickinson) was implanted between the L5 and L6 vertebrae to reach the lumbar enlargement of the spinal cord. The outer part of the catheter was plugged and fixed onto the skin on closure of the wound. Rats showing neurological deficits after the catheter implantation were euthanized. Drugs or vehicle were intrathecally injected via the implanted catheter in a 10 μl volume of solution followed by 10 μl of normal saline for flushing. Each injection lasted at least 5 min, and the needle remained in situ for 2 min before being withdrawn after an injection.
Western blotting
Equal amounts of protein (50 μg) from the spinal dorsal horn of rats were separated and electro-transferred onto PVDF membranes (Invitrogen, USA), which were probed with mouse anti-NR2B monoclonal antibody (1:500, Abcam, USA), Rabbit anti-NR2B (pTyr1472) polyclonal antibody (1:1000, Abcam, USA) and mouse anti-β-actin primary antibody (1:1000, Abcam, USA). Blots were washed and incubated in peroxidase-conjugated goat anti-rabbit IgG (1:5000, Abcam, USA) or goat anti-mouse IgG (1:5000, Abcam, USA). Bands were visualized using an ECL system.
Statistical analysis
All data were expressed as mean7S.E.M. One-way repeated measures analysis of variance (ANOVA) was used to determine whether there was a significant difference in standardized amplitude of EMG between control and IBS-like rat. After intrathecal injection of compounds, standardized data were analyzed using two-way repeated measures ANOVA with Bonferroni post hoc analysis. Western blot results were examined by one or two-way ANOVA with Student-Newman-Keuls (SNK) multiple comparisons post-hoc analysis. Po0.05 was considered to be statistically significant.
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